Campbell, E. J., Tesson, M., Doogan, F., Mohammed, Z. M.A., Mallon, E. and Edwards, J. (2016) The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 115(8), pp. 967-973. (doi: 10.1038/bjc.2016.206) (PMID:27657341)
|
Text
119997.pdf - Accepted Version 839kB |
Abstract
Background: The functional role of progesterone receptor (PR) signalling was previously unclear and PR testing in breast cancer is controversial. Recent defining work has highlighted the functional crosstalk that exists between the oestrogen receptor (ER) and PR. The purpose of this retrospective cohort study was to compare the prognostic value of the combined ER and PR score with either ER or PR alone. Methods: Tumour Allred ER and PR scores were reclassified as negative, low and high. The combined endocrine receptor (CER) was calculated as the average of the reclassified ER and PR scores, resulting in three groups: CER negative, impaired and high. Cox proportional hazards models were used to estimate disease-free survival (DFS) and breast cancer-specific survival (BCSS). Results: The CER was a more powerful predictor of 5-year DFS and BCSS than either ER or PR alone. In multivariate analysis that included ER, PR and CER, only CER remained an independent prognostic variable for 5-year DFS (hazard ratio (HR) 0.393; CI: 0.283–0.548, P¼ 0.00001) and BCSS (HR 0.553; CI: 0.423–0.722; P¼ 2.506 10 8 ). In ER-positive (ERþ ) patients impaired CER was an independent marker of poor outcome for 5-year DFS (HR 2.469; CI: 1.049–5.810; P¼ 0.038) and BCSS (HR 1.946; CI: 1.054–3.596; P¼ 0.033) in multivariate analysis that included grade, lymph node, tumour size, HER2 status and PR status. The results were validated in a separate cohort of patients. Conclusions: Combined endocrine receptor is a more powerful discriminator of patient outcome than either ER or PR alone. Economical and simple, it can identify risk in ERþ early breast cancer and potentially be used for adjuvant cytotoxic chemotherapy decision-making.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Mallon, Dr Elizabeth and Doogan, Dr Flora and Campbell, Dr Esther and Mohammed, Dr Zahra and Tesson, Dr Mathias and Edwards, Professor Joanne |
Authors: | Campbell, E. J., Tesson, M., Doogan, F., Mohammed, Z. M.A., Mallon, E., and Edwards, J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | British Journal of Cancer |
Publisher: | Cancer Research UK |
ISSN: | 0007-0920 |
ISSN (Online): | 1532-1827 |
Published Online: | 22 September 2016 |
Copyright Holders: | Copyright © 2016 Cancer Research UK |
First Published: | First published in British Journal of Cancer 115(8): 967-973 |
Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher |
University Staff: Request a correction | Enlighten Editors: Update this record